An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

Trial Details

NCT ID
NCT06487624
Phase
PHASE1
Sponsor
FBD Biologics Limited
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • HCB301
Locations (sample)
  • Greenville, South Carolina, United States|34.85262,-82.39401
  • Hangzhou, China|30.29365,120.16142
  • Hangzhou, China|30.29365,120.16142
  • Xuzhou, China|34.20442,117.28386
  • Yantai, China|37.47649,121.44081

Key Eligibility Criteria

  • Able to understand and be willing to sign the ICF.
  • Male and female subjects of ≥18 years of age.
  • Histologically/cytologically confirmed, locally advanced solid tumor:
  • subjects confirmed advanced solid tumors who have relapsed or refractory and should have no options for standard or approved therapies known to pot…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →